Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
about
Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancerThe Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.Hippo pathway mediates resistance to cytotoxic drugs.The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical DecisionsCost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patientsPrognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-studyNottingham Prognostic Index Plus: Validation of a clinical decision making tool in breast cancer in an independent series.Nottingham prognostic index plus (NPI+) predicts risk of distant metastases in primary breast cancer.From High-Throughput Microarray-Based Screening to Clinical Application: The Development of a Second Generation Multigene Test for Breast Cancer Prognosis.Anthracyclines and taxanes in the neo/adjuvant treatment of breast cancer: does the sequence matter?miRNAs as prognostic and therapeutic tools in epithelial ovarian cancer.Intratumor Heterogeneity Affects Gene Expression Profile Test Prognostic Risk Stratification in Early Breast CancerMammaPrint versus EndoPredict: Poor correlation in disease recurrence risk classification of hormone receptor positive breast cancer.[Gene expression analysis in breast cancer. A new diagnostic tool in pathology].
P2860
Q21089802-2F72BB31-84D8-4E53-8D35-849624C1181BQ34373936-C58F3A82-6D61-4408-A62A-70A787E908C1Q34555337-91FFA80E-6733-40CC-A792-A0C94FE37BD2Q34797928-5D230354-F32F-4EAA-AC32-B96DF5C68C0BQ35008290-87AD99C6-AEB6-47C2-9EC3-2321987FCCF1Q36678505-50FBE3FA-0FFC-4118-9524-0B652C4B0F28Q36873822-95A54F04-EFA5-405E-B423-78D4FBD006E1Q36908377-96278E54-5513-4191-95C9-2078DBA9FB49Q37214217-DDD8C76E-236D-4219-B911-431A141BF838Q38195674-3BD15D6D-A732-4FDB-95E6-8F76F7B55308Q38366731-635BCC2E-D689-4FBD-9011-0567B25ABA07Q39761803-B873C434-1917-4388-98A4-59DC544C19C8Q41545259-F69500C3-8572-48C8-82DC-BE03CFD3E116Q52882864-832BA033-FCBE-41AF-8443-F39F0D4F50AC
P2860
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@en
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@nl
type
label
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@en
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@nl
prefLabel
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@en
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@nl
P2860
P356
P1433
P1476
Genomic analyses to select patients for adjuvant chemotherapy: trials and tribulations.
@en
P2093
J S Reis-Filho
P2860
P304
P356
10.1093/ANNONC/MDS323
P478
23 Suppl 10
P577
2012-09-01T00:00:00Z